Achieve Life Sciences – Consensus Indicates Potential 455.6% Upside

Broker Ratings

Achieve Life Sciences found using ticker (ACHV) have now 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 100 and 21 and has a mean target at 45. Given that the stocks previous close was at 8.1 this now indicates there is a potential upside of 455.6%. The 50 day moving average now sits at 8.23 and the 200 day MA is 8.78. The market cap for the company is $48m. You can visit the company’s website by visiting: http://www.achievelifesciences.com

Achieve Life Sciences, a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index